8 recruiting, 6 completed, 5 not yet recruiting, 3 active not recruiting. 10 Phase 2, 4 Not applicable, 4 Phase 1, 2 Phase 4, 1 Phase 3.
Follow Metabolic Dysfunction-associated Steatohepatitis (MASH): new trials by email Literature Review of Metabolic Dysfunction-associated Steatohepatitis (MASH) trials Research Report on Metabolic Dysfunction-associated Steatohepatitis (MASH)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis QL2401 25 mg, QL2401 50 mg, QL2401 100 mg - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 132 | 2026-12-01 | 2026-10-22 |
| Nutrition Intervention Combined With Resmetirom for MASH Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 4 | Not yet recruiting | City University of New York | 120 | 2026-10-01 | 2026-07-06 |
| Isocaloric Navy-Bean Substitution in Adults With MASLD Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis | Not applicable | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 40 | 2026-09-01 | 2026-08-12 |
| A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis HRS-4729 Injection, HRS9531 Injection, HRS-4729 Injection Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 160 | 2026-08-14 | 2026-08-26 |
| Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH Pemvidutide, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 3 | Recruiting | Altimmune, Inc. | 1800 | 2026-07-30 | 2026-09-23 |
| A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) VV-14303 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 56 | 2026-07-30 | 2026-09-01 |
| A Prospective Study of Cold Exposure in Patients With MASH Water-Perfused Cooling Suit - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Not applicable | Active not recruiting | Renmin Hospital of Wuhan University | 11 | 2026-07-08 | 2026-09-16 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 150 | 2026-07-06 | 2026-10-26 |
| Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD stool sampling, dietary assessment, and collection of blood and urine samples - MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Not applicable | Recruiting | Hospices Civils de Lyon | 24 | 2026-06-16 | 2026-06-22 |
| A Study of CS060380 Tablets in Patients With MASH and Obesity semaglutide, CS060380, Placebo - Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity | Phase 2 | Active not recruiting | Cascade Pharmaceuticals, Inc | 130 | 2026-04-02 | 2026-08-10 |
| A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population No treatment given - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Completed | Novo Nordisk A/S | 1330 | 2025-10-02 | 2026-03-12 | |
| A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) UBT251, Placebo - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 156 | 2025-09-30 | 2025-11-20 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLD Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Completed | Corcept Therapeutics | 9 | 2025-08-22 | 2026-09-30 |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Placebo, IBI362 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 181 | 2025-06-20 | 2026-10-20 |
| To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH IMM-H014, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 / Phase 2 | Not yet recruiting | Changchun Intellicrown Pharmaceutical Co. LTD | 40 | 2025-06-10 | 2025-06-13 |
| Clinical Classification of MAFLD Based Liver Biopsy Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH) | Not yet recruiting | Beijing Friendship Hospital | 2000 | 2025-02-08 | 2025-02-12 | |
| Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM CS0159, CS0159 placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity | Not applicable | Completed | Shanghai Jiao Tong University School of Medicine | 62 | 2024-07-19 | 2025-06-03 |
| Fibrosis Lessens After Metabolic Surgery Metabolic surgery, Incretin-Based Therapy - Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease | Phase 4 | Recruiting | The Cleveland Clinic | 120 | 2024-07-11 | 2026-07-31 |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B) - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Completed | Corcept Therapeutics | 175 | 2023-10-25 | 2026-09-29 |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition ALN-HSD, Placebo - Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 120 | 2023-02-09 | 2026-10-08 |
Showing 20 of 22. Sign in to see all of them.
Liver Cirrhosis (5) · Non-alcoholic Fatty Liver Disease (5) · Fatty Liver (3) · Obesity (3) · Diabetes Mellitus, Type 2 (1) · Fibrosis (1) · Hepatitis (1)
Digestive System Diseases (9) · Liver Diseases (9) · Pathological Conditions, Signs and Symptoms (7) · Fatty Liver (5) · Pathologic Processes (5) · Fibrosis (4) · Body Weight (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3) · Overweight (3) · Signs and Symptoms (3) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1)
Bariatric Surgery (1) · CORT118335 (1) · Dietary Supplements (1) · Gastric Bypass (1) · Nutrition Assessment (1) · mazdutide (1) · semaglutide (1)
Corcept Therapeutics (2) · Regeneron Pharmaceuticals (2) · Altimmune, Inc. (1) · Beijing Friendship Hospital (1) · Cascade Pharmaceuticals, Inc (1) · Changchun Intellicrown Pharmaceutical Co. LTD (1) · City University of New York (1) · Eli Lilly and Company (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · General University Hospital, Prague (1) · Hospices Civils de Lyon (1) · Icahn School of Medicine at Mount Sinai (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Kriya Therapeutics, Inc. (1) · Novo Nordisk A/S (1)
United States (11) · China (8) · Puerto Rico (4) · Japan (3) · Canada (2) · France (2) · India (2) · Brazil (1) · Czechia (1) · Finland (1) · Germany (1) · Ireland (1) · Italy (1) · Kuwait (1) · Mexico (1)
Kavita Juneja, MD (2) · Ali Aminian, MD (1) · Hong You, PhD. / M.D. (1) · Qinglong Jin (1) · Weiqing Wang, Ph.D. (1) · Xiaotao Zhang, MD, PhD (1) · Yanhua Ding (1)